Pharmacokinetic analysis of 5-[18F]Fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma

Cancer Research

Volumn 57, Issue 16, 1997, Pages 3415-3423

  Kissel, Jutta ^a   Brix, Gunnar ^a   Bellemann, Matthias E ^a   Strauss, Ludwig G ^a   Dimitrakopoulou Strauss, Antonia ^a   Port, Rüdiger ^a   Haberkorn, Uwe ^a   Lorenz, Walter J ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADENOCARCINOMA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DRUG CLEARANCE; DRUG TISSUE LEVEL; HUMAN; LIVER CLEARANCE; LIVER METASTASIS; MICHAELIS CONSTANT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, CHEMICAL; RETROSPECTIVE STUDIES; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030763054     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Heidelberger, C., Chaudhuri, N. K., Danneberg, P., Mooren, D., Griesbach, L., Duschinsky, R., Schnitzer, R. J., Pleven, E., and Scheiner, J. Fluorinated pyrimidines: a new class of tumour-inhibitory compounds. Nature (Lond.), 179: 663-666, 1957.
2. Kemeny, N. The systemic chemotherapy of hepatic metastases. Semin. Oncol., 10: 148-158, 1983.
3. Myers, C. E. The pharmacology of the fluoropyrimidines. Pharmacol. Rev., 33: 1-15, 1981.
4. Strauss, L. G., and Conti, P. S. The application of PET in clinical oncology. J. Nucl. Med., 32: 623-684, 1991.
5. Dimitrakopoulou, A., Strauss, L. G., Clorius, J. H., Ostertag, H., Schlag, P., Heim, M., Oberdorfer, F., Helus, F., Haberkorn, U., and van Kaick, G. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J. Nucl. Med., 34: 1075-1081, 1993.
6. 18F]uracil positron emission tomography (PET). Eur. J. Cancer, 29A: 1682-1686, 1993.
7. Wolf, W., Albright, M. J., Silver, M. S., Weber, H., Reichardt, U., and Sauer, R. Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn. Reson. Imaging, 5: 165-169, 1987.
8. 19F magnetic resonance spectroscopy. Br. J. Radiol., 63: 547-553, 1990.
9. Semmler, W., Bachert-Baumann, P., Gückel, F., Ermark, F., Schlag, P., Lorenz, W. J., and van Kaick, G. Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Radiology, 174: 141-145, 1990.
10. 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc. Natl. Acad. Sci. USA, 87: 492-496, 1990.
11. 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J. Clin. Oncol., 8: 1868-1873, 1990.
12. 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma. Magn. Reson. Imaging, 12: 497-511, 1994.
13. 19F MR imaging. Magn. Reson. Med., 34: 302-307, 1995.
14. 19F MRI: a comparative animal study. Nucl. Med. Biol., 23: 879-906, 1996.
15. 19F nuclear magnetic resonance spectroscopy. Cancer Res., 51: 5806-5812, 1991.
16. 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res., 48: 1680-1688, 1988.
17. Malet-Martino, M. C., Martino, R., Lopez, A., Beteille, J. P., Bon, M., Bernadou, J., and Armand, J. P. New approach to metabolism of 5′-deoxy-5-fluorouridine in humans with fluorine-19 NMR. Cancer Res., 13: 31-35, 1984.
18. 19F MRS studies of fluoropyrimidine chemotherapy: a review. NMR Biomed., 2: 133-141, 1989.
19. 19F NMR spectroscopy. NMR Biomed., 4: 274-278, 1991.
20. 19F magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver. Cancer Res., 51: 1384-1390, 1991.
21. Sijens, P. E., Baldwin, and Ng, T. C. Multinuclear MR investigations of the metabolic response of the murine RIF-1 tumor to 5-fluorouracil chemotherapy. Magn. Reson. Med., 9: 373-385, 1991.
22. 19F NMR. Br. J. Cancer, 50: 113-117, 1984.
23. 18F-labeled 5-fluorouracil of very high purity. J. Labelled Compd. Radiopharm., 27: 137-145, 1989.
24. Hoverath, H., Kübler, W. K., Ostertag, H., Doll, J., Ziegler, S. I., Knopp, M. V., and Lorenz, W. J. Scatter correction in the transaxial slices of a whole-body positron emission tomograph. Phys. Med. Biol., 38: 717-728, 1993.
25. Ostertag, H., Kübler, W. K., Doll, J., and Lorenz, W. J. Measured attenuation correction methods. Eur. J. Nucl. Med., 15: 722-726, 1989.
26. Shepp, L. A., and Vardi, Y. Maximum likelihood reconstruction for emission tomography. IEEE Trans. Med. Imaging, 1: 113-122, 1982.
27. Lewitt, R. M., and Muehllehner, G. Accelerated iterative reconstruction for positron emission tomography based on the EM algorithm for maximum likelihood estimation. IEEE Trans. Med. Imaging, 5: 16-22, 1986.
28. Brix, G., Doll, J., Bellemann, M. E., Trojan, H., Haberkorn, U., Schmidlin, P., and Ostertag, H. Use of scanner characteristics in iterative image reconstruction for high-resolution PET studies of small animals. Eur. J. Nucl. Med., in press, 1997.
29. Au, J. L-S., Walker, J. S., and Rustum, Y. Pharmacokinetic studies of 5-fluorouracil and 5′-deoxy-5-fluorouridine in rats. J. Pharmacol. Exp. Ther., 227: 174-180, 1983.
30. Bourke, R. S., West, C. R., Cheda, G., and Tower, D. B. Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res., 33: 1735-1746, 1973.
31. El Sayed, Y. M., and Sadee, W. The fluoropyrimidines. In: M. M. Ames, G. Powis, and J. S. Kovach (eds.), Pharmacokinetics of Anticancer Agents in Humans, pp. 209-227. Amsterdam: Elsevier Science Publishers, 1983.
32. Collins, J. M., Dedrick, R. L., King, F. G., Speyer, J. L., and Myers, C. E. Nonlinear pharmacokinetic models for 5-fluorouracil in men: intravenous and intraperitoneal routes. Clin. Pharmacol. Ther., 28: 235-246, 1980.
33. Naguib, F. N. M., el Kouni, M. H., and Cha, S. Enzymes of uracil catabolism in normal and neoplastic human tissue. Cancer Res., 45: 5405-5412, 1985.
34. Ritschel, W. A. Handbook of Basic Pharmacokinetics, Including Clinical Applications, p. 134. Hamilton: Drug Intelligence Publications, 1992.
35. van Thiel, D. H., Hagler, N. G., Schade, R. R., Skolnik, M. L., Pollit Heyl, A., Rosenblum, E., Gavaler, J. S., and Penkrot, R. J. In vivo hepatic volume determination using sonography and computed tomography. Gastroenterology, 88: 1812-1817, 1985.
36. duBois, D., and duBois, E. F. A formula to estimate the approximate surface area in height and weight be known. Arch. Intern. Med., 17: 863-871, 1916.
37. DeLand, H., and North, W. Relationship between liver size and body size. Radiology, 91: 1195-1198, 1968.
38. Heggie, G. D., Sommadossi, J-P., Cross, D. S., Huster, W. J., and Diasion, R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res., 47: 2203-2206, 1987.
39. Port, R. E., Schlemmer, H-P., and Bachert, P. Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach. Eur. J. Clin. Pharmacol., 47: 187-193, 1994.
40. Ensminger, W. D., Rosowsky, A., Levin, D. C., Glode, M., Come, S., Steele, G., and Frei, E. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res., 38: 3784-3792, 1978.
41. Etienne, M. C., Cheradame, S., Fischel, J. L., Formento, P., Dassonville, O., Renee, N., Schneider, M., Thyss, A., Demard, F., and Milano, G. Response of fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J. Clin. Oncol., 13: 1663-1670, 1995.
42. Wagner, J. G., Gyves, J. W., Stetson, P. L., Walher-Andrews, S. C., Wollner, I. S., Cochran, M. K., and Ensminger, W. D. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res., 46: 1499-1506, 1986.
43. Sotos, G. A., Grogan, L., and Allegra, C. J. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat. Rev., 20: 11-49, 1994.